← Leaderboards
Keisha Nicole Hardeman
Vanderbilt University
$154,505
Attributed
$154,505
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $42.2K · FY2012–16$50K$37.5K$25K$12.5K$0
'12
'13
'14
'15
'16
Funding mix
By agency
NIH$154,505 · 1
By mechanism
F31$154,505 · 1
Top collaborators
No co-investigators on record.
Most similar at Vanderbilt University
Same institution · by research overlap
- Richard Kp Benninger$10,744,798
- Nancy Joan Brown$32,445,188
- Robert A Kesterson$10,120,274
- Carlos L Arteaga$27,881,034
- Youfei Guan$2,192,224
Others in their field
Top investigators on “Complement”
- Charles Mattias Mountain · Association Of Universities For Research In Astronomy, Inc.$128,874,888
- Wafaa M. El-Sadr · Columbia University Health Sciences$101,800,876
- Myron S Cohen · Family Health International$101,800,876
- Steve Riordan · Westat, Inc.$94,143,268
- David R. Weir · University Of Michigan At Ann Arbor$93,718,087
- Stuart L Schreiber · Harvard University (Medical School)$88,512,978
Research focus
ComplementCombined Modality TherapyChickensAerobic GlycolysisChorioallantoic MembraneChronicAnimal ModelAcuteBreast Cancer CellAntidiabetic DrugsApoptosisAnalogBaseCancer TherapyCancer TypeBiochemicalBiological ModelsCell CycleCell DeathCell LineCell RespirationCellsCessation Of LifeCoupling
Grant awards (5)
Targeting Altered Redox Metabolism in Lapatinib-resistant Breast Cancer$21,948
F31 · FY2016 · CA · contact PI
Targeting Altered Redox Metabolism in Lapatinib-resistant Breast Cancer$27,766
F31 · FY2015 · CA · contact PI
Targeting Altered Redox Metabolism in Lapatinib-resistant Breast Cancer$27,322
F31 · FY2014 · CA · contact PI
Targeting Altered Redox Metabolism in Lapatinib-resistant Breast Cancer$35,237
F31 · FY2013 · CA · contact PI
Targeting Altered Redox Metabolism in Lapatinib-resistant Breast Cancer$42,232
F31 · FY2012 · CA · contact PI